belantamab mafodotin,idecabtagene vicleucel
gsk,2seventy bio,bms
['blenrep', 'karmma', 'ide-cel']
#ash22 exposure to anti bcma therapies (76% blenrep) prior to ide-cel showed orr of 74% vs 88% in those who did not have prior bcma directed therapy...mva showed this factor lowered likelyhood of getting to a cr.... much more needs to be learnt about sequencing these therapies! 
MD